Tom 11, Supl. B (2025)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2025-03-08
Wyświetlenia strony
13
Wyświetlenia/pobrania artykułu
4
Wprowadzenie
Streszczenie
Brak
Referencje
- Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022; 33(11): 1097–1118.
- Lu YS, Im SA, Colleoni M, et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022; 28(5): 851–859.
- Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19(7): 904–915.
- Burris HA, Chan A, Bardia A, et al. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. Br J Cancer. 2021; 125(5): 679–686.
- Kufel-Grabowska J, Wasąg B. Diagnosis and treatment of patients with breast cancer and mutation in the BRCA1/2 genes. Oncology in Clinical Practice. 2024; 20(3): 222–228.
- Bozkaya Y, Ay B. Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer. Breast J. 2020; 26(4): 773–774.
- Messer JA, Ekinci E, Patel TA, et al. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report. Rep Pract Oncol Radiother. 2019; 24(3): 276–280.
- Bosacki C, Bouleftour W, Sotton S, et al. CDK 4/6 inhibitors combined with radiotherapy: A review of literature. Clin Transl Radiat Oncol. 2021; 26: 79–85.
